Earnings call transcript: TCM Group's Q2 2025 shows steady performance

TCM Group reported Q2 2025 earnings with revenue of DKK 349 million, a slight miss against forecasts, yet delivered robust operational performance highlighted by a 20% increase in adjusted EBIT and improved gross margins to 23.7%. The stock experienced a minor 0.28% decline, reflecting a neutral market reception that weighed the revenue miss against strong underlying financial health, evidenced by a Piotroski Score of 9. Looking ahead, the company narrowed its 2025 guidance for revenue to DKK 1.25-1.3 billion and adjusted EBIT to DKK 90-110 million, anticipating B2B segment recovery and progressing with the acquisition of Silever, despite acknowledging a slower consumer order intake in Q2.

Analysis

TCM Group's Q2 2025 results present a mixed but fundamentally strong picture. While revenue of DKK 349 million marginally missed the DKK 350 million forecast, the company demonstrated significant operational leverage, posting a 20% year-over-year increase in adjusted EBIT to DKK 34 million. This bottom-line strength was driven by a notable gross margin expansion to 23.7% from 21.5%, attributed to higher average selling prices and a strategic deferral of supplier price hikes. The market's reaction was muted, with a minor 0.28% stock decline, suggesting investors are weighing the slight revenue miss against robust underlying fundamentals, which are further underscored by a perfect Piotroski Score of 9. Looking forward, management has narrowed its full-year 2025 guidance, trimming the top end of its revenue and EBIT outlook. This revision reflects caution stemming from a slowdown in B2C order intake observed in the latter half of Q2, which the CEO linked to consumer hesitation despite solid store traffic. Future performance is contingent on the B2C market's recovery post-summer and a rebound in the B2B segment, while the impending Silever acquisition is positioned as a long-term strategic enhancement with minimal near-term financial impact.

Key Decisions for Investors

• Investors should closely monitor leading indicators of consumer demand and order intake trends for Q3, as management highlighted a critical divergence between store traffic and final sales conversions.
• Scrutinize gross margin performance in the second half of the year, as the CFO indicated that the positive impact from deferred supplier price hikes may not be fully sustainable.
• Evaluate the recovery pace of the B2B segment, especially orders from house builders, as this has been identified as a key determinant for achieving the upper end of the revised 2025 guidance.
• Given the strong operational performance and financial health metrics against a neutral market reaction, consider the stock's valuation, as any stabilization in consumer order flow could present a favorable entry point.